

Locally-Advanced Ulcerative T4b Breast Cancer; Are Reconstructive Attempts Feasible?

Aditya Sood MD, MBA, Lily Daniali, MD, Kameron Razzedah BS, Edward S. Lee MD, Jonathan Keith MD

Rutgers University - New Jersey Medical School Division of Plastic Surgery Newark, NJ USA

*Nothing to disclose

Background

- •A subset of women with locally-advanced breast cancer (LABC) present with fungating tumor mass eroding and infiltrating the surrounding breast skin (T4b).
 - -Present in 5-10% of cases in economically developed countries
 - -20-25% of cases worldwide
- •These patients often present with chronic pain, large open wounds, frequent infections, malodorous drainage, social isolation, and general debilitation that present enormous therapeutic challenges.
- Optimal surgical management of LABC continues to be a source of controversy.



Background cont.

- Newark, NJ, USA (vs. total US population)
 - Total population 2013: 278,427 / 8,900,000
 - Foreign born 2013: 26.9% / 20.8%
 - Primary language not English: 45% / 29.6%
 - Bachelor's or higher 2008-12: 12.5% / 35.4%

Materials/Methods

- Single-center experience (IRB approved)
- Retrospective review
- 12 treated patients from 2011-2014
 - Received reconstructive surgeries following resection of fungating T4b breast tumors



Results

 Table 1: T4b Fungating Breast Tumor Patient Demographic & Social Characteristics

Variable	Value (%)
No. of Patients	12
Age, years	
Mean	52.6
Range	33-74
Race	
African-American	7 (50)
Caucasian	1 (8)
Hispanic	4 (33)
Social History	
Recent US Immigrant (<2 years)	1 (8)
Recent Homelessness (<1 year)	1 (8)
Currently Unemployed	5 (42)
English Speaking	5 (42)
Living Alone	4 (33)



T4b Reconstruction Considerations

Results cont.

 Table 2: Clinical Presentation & Pre-Operative Assessment of the Patient with a Fungating T4b breast tumor

Reconstruction Considerations		
Variable	Value (%)	
Location of First Presentation		
Emergency Department	3 (25)	
Charity Care Clinic/ Community Clinic	7 (58)	
Private Office	2 (17)	
Chief Complaint on Presentation		
Open wound and/or skin involvement	12 (100)	
Pain	8 (66)	
Malodorous Drainage	3 (25)	
Breast mass increasing in size	3 (25)	
Patients Reason for Delayed Presentation		
Embarrassment	2 (17)	
Psychiatric Condition	3 (25)	
Prior Misdiagnosis	1 (8)	
Fear of Treatment	3 (25)	
Tumor Size		
Mean (cm ²⁾	810.2	
<300 cm ²	6 (50)	
300-600 cm ²	2 (17)	
>600 cm ²	3 (25)	
Hemodynamic Instability on Arrival	2 (17)	
Neo-adjuvant Chemotherapy	4 (42)	
Neo-adjuvant Radiotherapy	2 (17)	
Extent of Disease as Assessed by Imaging		
Loco-regional Spread	3 (25)	
Distant Metastasis	6 (50)	



Results cont.

• Table 3:Pre-Operative Laboratory Characteristics

Variable	Mean	SD
Albumin	3.4	1.0
Hemoglobin	9.8	2.6
WBC	12.8	10.5
Platelets	316.9	139.8
INR	1.1	0.17
CRP	0.65	0.15

^{*}Notably: Two patients had presented in shock, with one patient having a hemoglobin of 4.2



T₄b

Results cont.

 Table 4: Characteristics of Oncologic
 & Reconstructive Management of T4b **Fungating Breast Tumors**



Variable	Value (%)
Oncologic Management	
Breast	
Modified Radical Mastectomy with Axillary Lymph Node Dissection	9 (75)
Radical Mastectomy	2 (17)
Chest Wall	
Ant pec major fascia resected	4 (33)
Additional chest wall muscles resected	2 (17)
Pathology	
Breast specimen with clear margins (R0)	7 (58)
Reconstructive Surgery	
Area requiring reconstruction (cm ²⁾	
Mean	473
>300	2 (17)
300-600	6 (50)
601-900	4 (33)
Procedures Performed	
Thoracoepigastric Advancement Flap	4 (33)
Latissimus Dorsi Flap	5 (41)
Trapezius Flap	1 (8)
Extended vertical & transverse rectus abdominus flap	1 (8)
Split-thickness skin graft	6 (50)
Timing of Reconstructive Surgery	
Immediate	10 (83)
Delayed	2 (17)
Total # of Reconstructive Surgeries	
1	7 (58)
2	5 (41)



Results cont.

• **Table 5:** Postoperative outcomes.

	Value (%)
Surgical Site at 6 weeks follow-up	
Healed	7 (58)
Open wound requiring dressings	3 (25)
Not reported	2 (17)
Post-operative Pain Palliation	
Reduced pain	9 (75)
Persistent or increased pain	2 (17)
Not reported	1 (8)
Post-operative Wound Palliation	
Improved wound qualities (odor, drainage)	10 (84)
Unimproved wound qualities	1 (8)
Not reported	1 (8)
Adjuvant Therapy	
Chemotherapy	4 (33)
Radiation	1 (8)



Results cont.

• **Table 5c.** Postoperative complications.

	Value (%)
Persistent wound drainage	2 (17)
Dehiscience requiring OR revision	1 (8)
Infection requiring course of antibiotics	1 (8)

Case 1

- 61 yoF, Haitian descent, presented to the clinic with pain of Right breast, arm, back pain. Found to have a 15 x 13.5 x 11 cm lateral breast mass with peu d'orange and ulceration.
- Dx: inflammatory breast cancer with axillary lymphadenopathy and no distant mets.
- Treatment: neo-adjuvant chemotherapy, MRM and LND
- Wound: 884 cm2





Case 1 cont.

- Immediate reconstruction with a latissimus myocutaneous flap and reverse abdominoplasty.
- Hospital stay 4 days, discharged with nursing care and outpatient chemotherapy.
- Reported improved pain, no complications.
- Postoperative survival: 294 days



Case 2

- 38 yoF, Hispanic descent, presented to the clinic complaining of pain in her chest with movement of her arm. Found to have a left lateral breast ulcerative lesion measuring 9 x 8 x4 cm.
- Dx: Invasive ductal carcinoma with metastisis.
- Treatment: neo-adjuvant chemotherapy, MRM, LND
- Wound: 300 cm2





Case 2 cont.

- Immediate reconstruction with advancement of local axillary skin and STSG 300 cm2.
- Hospital stay was 6 days. Received postoperative radiation.
- Reported improved pain, no complications.
- Postoperative survival: living





*One month postop

Conclusions

- LABC continues to be the presenting form of disease in a significant percentage of breast cancer patients.
- Microsurgical breast reconstruction techniques are reliable and efficacious in palliating pain and reducing wound care needs in patients with fungating T4b breast tumors.
- Fasciocutaneous flaps (thoracoepigastric) and latissimus dorsi myocutaneous flaps were the most commonly utilized coverage options in our cohort.
- Non-English speaking, social isolation, and psychiatric illness all play a part in delayed presentation.